カテゴリ： Transparency Market Research, 世界, 医療/バイオ

うっ血性心不全治療薬の世界市場2023～2031：うっ血性心不全種類別

■ 英語タイトル：Congestive Heart Failure Drugs Market (Type of Congestive Heart Failure: Left-sided Heart Failure, Right-sided Heart Failure, and High-output Heart Failure) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

調査会社Transparency Market Research社が発行したリサーチレポート（データ管理コード：TMR23MA032）■ 発行会社/調査会社：Transparency Market Research
■ 商品コード：TMR23MA032
■ 発行日：2023年3月29日
■ 調査対象地域：北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ
■ 産業分野：医薬品
■ ページ数：162
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,795 ⇒換算￥880,840見積依頼/購入/質問フォーム
Multi User（5名様閲覧）USD8,795 ⇒換算￥1,336,840見積依頼/購入/質問フォーム
Corporate License（法人閲覧）USD11,795 ⇒換算￥1,792,840見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Transparency Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[うっ血性心不全治療薬の世界市場2023～2031：うっ血性心不全種類別]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Transparency Market Research社の当調査レポートでは、世界のうっ血性心不全治療薬市場規模が、2023年の67億ドルから2031年に135億ドルとなり、予測期間中に年平均成長率7.6%で拡大すると展望しています。本書は、うっ血性心不全治療薬の世界市場にフォーカスし、市場状況や今後の動向などをまとめた資料です。序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、うっ血性心不全種類別（左心不全、右心不全、高拍出性心不全）分析、治療薬クラス別（ACE阻害剤、アンジオテンシンⅡ受容体拮抗薬、β遮断薬、ミネラロコルチコイド受容体拮抗薬、その他）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況など、以下の構成で掲載しています。また、市場参入企業として、Bayer AG、Novartis AG、Merck & Co., Inc.、AstraZeneca、Bristol-Myers Squibb Company、Amgen, Inc.、Boehringer Ingelheim International GmbH、Pfizer, Inc.、Johnson & Johnson Services, Inc.、Eli Lilly and Companyなどの情報が含まれています。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・主要インサイト
・世界のうっ血性心不全治療薬市場規模：うっ血性心不全種類別
- 左心不全の市場規模
- 右心不全の市場規模
- 高拍出性心不全の市場規模
・世界のうっ血性心不全治療薬市場規模：治療薬クラス別
- ACE阻害剤の市場規模
- アンジオテンシンⅡ受容体拮抗薬の市場規模
- β遮断薬の市場規模
- ミネラロコルチコイド受容体拮抗薬の市場規模
- その他治療薬クラスの市場規模
・世界のうっ血性心不全治療薬市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界のうっ血性心不全治療薬市場規模：地域別
- 北米のうっ血性心不全治療薬市場規模
- ヨーロッパのうっ血性心不全治療薬市場規模
- アジア太平洋のうっ血性心不全治療薬市場規模
- 中南米のうっ血性心不全治療薬市場規模
- 中東・アフリカのうっ血性心不全治療薬市場規模
・競争状況

Congestive Heart Failure Drugs Market – Scope of Report
TMR’s report on the global congestive heart failure drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global congestive heart failure drugs market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global congestive heart failure drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the congestive heart failure drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global congestive heart failure drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global congestive heart failure drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global congestive heart failure drugs market.

The report delves into the competitive landscape of the global congestive heart failure drugs market. Key players operating in the global congestive heart failure drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global congestive heart failure drugs market profiled in this report.

Key Questions Answered in Global Congestive Heart Failure Drugs Market Report
• What is the sales/revenue generated by congestive heart failure drugs across all regions during the forecast period?
• What are the opportunities in the global congestive heart failure drugs market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Congestive Heart Failure Drugs Market – Research Objectives and Research Approach
The comprehensive report on the global congestive heart failure drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global congestive heart failure drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global congestive heart failure drugs market.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Congestive Heart Failure Drugs Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Congestive Heart Failure Drugs Market Analysis and Forecast, 2017–2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Key Industry Events
    5.2. Pipeline Analysis
    5.3. Heart Failure Diseases Prevalence: Overview
6. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Type of Digestive Heart Failure
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031
        6.3.1. Left-sided Heart Failure
        6.3.2. Right-sided Heart Failure
        6.3.3. High-output Heart Failure
    6.4. Market Attractiveness Analysis, by Type of Digestive Heart Failure
7. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Drug Class
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Drug Class, 2017–2031
        7.3.1. ACE Inhibitors
        7.3.2. Angiotensin-2 Receptor Blockers
        7.3.3. Beta Blockers
        7.3.4. Mineralocorticoid Receptor Antagonists
        7.3.5. Diuretics
        7.3.6. Ivabradine
        7.3.7. Sacubitril Valsartan
        7.3.8. Others (digoxin etc.)
    7.4. Market Attractiveness Analysis, by Drug Class
8. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Distribution Channel
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Distribution Channel, 2017–2031
        8.3.1. Hospitals Pharmacies
        8.3.2. Retail Pharmacies
        8.3.3. Online Pharmacies
    8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region
10. North America Congestive Heart Failure Drugs Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031
        10.2.1. Left-sided Heart Failure
        10.2.2. Right-sided Heart Failure
        10.2.3. High-output Heart Failure
    10.3. Market Value Forecast, by Drug Class, 2017–2031
        10.3.1. ACE Inhibitors
        10.3.2. Angiotensin-2 Receptor Blockers
        10.3.3. Beta Blockers
        10.3.4. Mineralocorticoid Receptor Antagonists
        10.3.5. Diuretics
        10.3.6. Ivabradine
        10.3.7. Sacubitril Valsartan
        10.3.8. Others (digoxin etc.)
    10.4. Market Value Forecast, by Distribution Channel, 2017–2031
        10.4.1. Hospitals Pharmacies
        10.4.2. Retail Pharmacies
        10.4.3. Online Pharmacies
    10.5. Market Value Forecast, by Country, 2017–2031
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Type of Digestive Heart Failure
        10.6.2. By Drug Class
        10.6.3. By Distribution Channel
        10.6.4. By Country
11. Europe Congestive Heart Failure Drugs Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031
        11.2.1. Left-sided Heart Failure
        11.2.2. Right-sided Heart Failure
        11.2.3. High-output Heart Failure
    11.3. Market Value  Forecast, by Drug Class, 2017–2031
        11.3.1. ACE Inhibitors
        11.3.2. Angiotensin-2 Receptor Blockers
        11.3.3. Beta Blockers
        11.3.4. Mineralocorticoid Receptor Antagonists
        11.3.5. Diuretics
        11.3.6. Ivabradine
        11.3.7. Sacubitril Valsartan
        11.3.8. Others (digoxin etc.)
    11.4. Market Value Forecast, by Distribution Channel, 2017–2031
        11.4.1. Hospitals Pharmacies
        11.4.2. Retail Pharmacies
        11.4.3. Online Pharmacies
    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Italy
        11.5.5. Spain
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Type of Digestive Heart Failure
        11.6.2. By Drug Class
        11.6.3. By Distribution Channel
        11.6.4. By Country/Sub-region
12. Asia Pacific Congestive Heart Failure Drugs Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031
        12.2.1. Left-sided Heart Failure
        12.2.2. Right-sided Heart Failure
        12.2.3. High-output Heart Failure
    12.3. Market Value  Forecast, by Drug Class, 2017–2031
        12.3.1. ACE Inhibitors
        12.3.2. Angiotensin-2 Receptor Blockers
        12.3.3. Beta Blockers
        12.3.4. Mineralocorticoid Receptor Antagonists
        12.3.5. Diuretics
        12.3.6. Ivabradine
        12.3.7. Sacubitril Valsartan
        12.3.8. Others (digoxin etc.)
    12.4. Market Value Forecast, by Distribution Channel, 2017–2031
        12.4.1. Hospitals Pharmacies
        12.4.2. Retail Pharmacies
        12.4.3. Online Pharmacies
    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.5.1. China
        12.5.2. Japan
        12.5.3. India
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Type of Digestive Heart Failure
        12.6.2. By Drug Class
        12.6.3. By Distribution Channel
        12.6.4. By Country/Sub-region
13. Latin America Congestive Heart Failure Drugs Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031
        13.2.1. Left-sided Heart Failure
        13.2.2. Right-sided Heart Failure
        13.2.3. High-output Heart Failure
    13.3. Market Value Forecast, by Drug Class, 2017–2031
        13.3.1. ACE Inhibitors
        13.3.2. Angiotensin-2 Receptor Blockers
        13.3.3. Beta Blockers
        13.3.4. Mineralocorticoid Receptor Antagonists
        13.3.5. Diuretics
        13.3.6. Ivabradine
        13.3.7. Sacubitril Valsartan
        13.3.8. Others (digoxin etc.)
    13.4. Market Value Forecast, by Distribution Channel, 2017–2031
        13.4.1. Hospitals Pharmacies
        13.4.2. Retail Pharmacies
        13.4.3. Online Pharmacies
    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Type of Digestive Heart Failure
        13.6.2. By Drug Class
        13.6.3. By Distribution Channel
        13.6.4. By Country/Sub-region
14. Middle East & Africa Congestive Heart Failure Drugs Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031
        14.2.1. Left-sided Heart Failure
        14.2.2. Right-sided Heart Failure
        14.2.3. High-output Heart Failure
    14.3. Market Value  Forecast, by Drug Class, 2017–2031
        14.3.1. ACE Inhibitors
        14.3.2. Angiotensin-2 Receptor Blockers
        14.3.3. Beta Blockers
        14.3.4. Mineralocorticoid Receptor Antagonists
        14.3.5. Diuretics
        14.3.6. Ivabradine
        14.3.7. Sacubitril Valsartan
        14.3.8. Others (digoxin etc.)
    14.4. Market Value Forecast, by Distribution Channel, 2017–2031
        14.4.1. Hospitals Pharmacies
        14.4.2. Retail Pharmacies
        14.4.3. Online Pharmacies
    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.5.1. GCC Countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Type of Digestive Heart Failure
        14.6.2. By Drug Class
        14.6.3. By Distribution Channel
        14.6.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player – Competition Matrix (by tier and size of companies)
    15.2. Market Share Analysis, by Company, 2021
    15.3. Company Profiles
        15.3.1. Bayer AG
            15.3.1.1. Company Overview
            15.3.1.2. Financial Overview
            15.3.1.3. Product Portfolio
            15.3.1.4. Business Strategies
            15.3.1.5. Recent Developments
        15.3.2. Novartis AG
            15.3.2.1. Company Overview
            15.3.2.2. Financial Overview
            15.3.2.3. Product Portfolio
            15.3.2.4. Business Strategies
            15.3.2.5. Recent Developments
        15.3.3. Merck & Co., Inc.
            15.3.3.1. Company Overview
            15.3.3.2. Financial Overview
            15.3.3.3. Product Portfolio
            15.3.3.4. Business Strategies
            15.3.3.5. Recent Developments
        15.3.4. AstraZeneca
            15.3.4.1. Company Overview
            15.3.4.2. Financial Overview
            15.3.4.3. Product Portfolio
            15.3.4.4. Business Strategies
            15.3.4.5. Recent Developments
        15.3.5. Bristol-Myers Squibb Company
            15.3.5.1. Company Overview
            15.3.5.2. Financial Overview
            15.3.5.3. Product Portfolio
            15.3.5.4. Business Strategies
            15.3.5.5. Recent Developments
        15.3.6. Amgen, Inc.
            15.3.6.1. Company Overview
            15.3.6.2. Financial Overview
            15.3.6.3. Product Portfolio
            15.3.6.4. Business Strategies
            15.3.6.5. Recent Developments
        15.3.7. Boehringer Ingelheim International GmbH
            15.3.7.1. Company Overview
            15.3.7.2. Financial Overview
            15.3.7.3. Product Portfolio
            15.3.7.4. Business Strategies
            15.3.7.5. Recent Developments
        15.3.8. Pfizer, Inc.
            15.3.8.1. Company Overview
            15.3.8.2. Financial Overview
            15.3.8.3. Product Portfolio
            15.3.8.4. Business Strategies
            15.3.8.5. Recent Developments
        15.3.9. Johnson & Johnson Services, Inc.
            15.3.9.1. Company Overview
            15.3.9.2. Financial Overview
            15.3.9.3. Product Portfolio
            15.3.9.4. Business Strategies
            15.3.9.5. Recent Developments
        15.3.10. Eli Lilly and Company
            15.3.10.1. Company Overview
            15.3.10.2. Financial Overview
            15.3.10.3. Product Portfolio
            15.3.10.4. Business Strategies
            15.3.10.5. Recent Developments

List of Tables

Table 01: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017‒2031

Table 02: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 03: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017‒2031

Table 07: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 08: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017‒2031

Table 11: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 12: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017‒2031

Table 15: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 16: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 18: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017‒2031

Table 19: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 20: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 22: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017‒2031

Table 23: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 24: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • RAS作用薬の世界市場2023-2031：産業分析、規模、シェア、成長、動向、予測
  • 強心薬の世界市場2023～2031：薬剤別
  • 抗凝血剤の世界市場2022～2031：薬物クラス別
  • 臓器移植拒絶反応治療薬の世界市場2023-2031：産業分析、規模、シェア、成長、動向、予測
  • バソプレシン拮抗薬の世界市場2023～2031：用途別
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(TMR23MA032 )"うっ血性心不全治療薬の世界市場2023～2031：うっ血性心不全種類別" (英文：Congestive Heart Failure Drugs Market (Type of Congestive Heart Failure: Left-sided Heart Failure, Right-sided Heart Failure, and High-output Heart Failure) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031)はTransparency Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。